| ［1］Velayudham LS，Farrell GC. Drug-induced cholestasis. Expert Opin Drug Saf，2003，2（3）：287-304.［2］Bjornsson ES, Jonasson JG. Drug-induced cholestasis. Clin Liver Dis,2013,17(2):191-209.［3］陈晓霞，杨海敏，姜娜. 110例药物性肝炎的病因和临床分析.实用医技杂志，2008，15（13）：1728-1730.［4］Lazerow SK，Abdi MS，Lewis JH. Drug-induced liver disease 2004. Curr Opin Gastroenterol，2005，21（3）：283-292.［5］Bleibel W，Kim S，D'Silva K，et al. Drug-induced liver injury： review article. Dig Dis Sci，2007,52（10）:2463-2471. ［6］彭东晖,汪锺贤.关于抗结核药物副作用的几个问题.临床荟萃，1986，1(11)：21-25.［7］肖成志. 第一线抗结核药物的副作用.中华结核和呼吸杂志，1979，2（3）:227.［8］郭英江，崔德键. 抗结核药所致肝损害.中华结核和呼吸杂志,1998,21（5）:308-309.［9］夏愔愔，詹思延. 国内抗结核药物不良反应发生率的综合分析.中华结核和呼吸杂志,2007, 30(6):419-423.［10］Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol,2008,23(2): 192-202.［11］雷建平,予季. 呼吸系统救护治疗学.南昌:江西科学技术出版社，2008.［12］Girling DJ. The hepatic toxicity of antituberculosis regimens containing isoniazid, rifampicin and pyrazinamide. Tubercle,1978,59(1):13-32.［13］刘向宏，王一丁，潘丽芳，等. 喹诺酮类药物研究进展及毒性分析.辽宁化工，2010,39(4): 431-434.［14］吴敏，吴洪文，李锦燊.氨基糖苷类药物的不良反应及防治对策.抗感染药学,2008,5(4):252-254.［15］程辉跃. HPLC法测定帕司烟肼片中对氨基水杨酸和异烟肼的含量.药物分析杂志，2000, 20(3): 186-188.［16］Hussain Z, Kar P, Husain SA. Antituberculosis drug-induced hepatitis: risk factors，prevention and managerment. Indian J Exp Biol，2003，41(11):1226-1232. ［17］Deng R, Yang T, Wang Y, et al. CYP2E1 RsaI/PstI polymorphism and risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis，2012，16(12):1574-1581. ［18］Sun F, Chen Y, Xiang Y, et al. Drug-metabolising enzyme polymorphisms and predisposition to anti-tuberculosis drug-induced liver injury: a meta-analysis. Int J Tuberc Lung Dis，2008，12(9):994-1002. ［19］Hercus CG, Khoo JK, Jones TE. A case of hyperacute hepatotoxicity in response to tuberculosis therapy. Int J Tuberc Lung Dis，2012，16(12):1709-1710.［20］Yimer G, Ueda N, Habtewold A, et al. Pharmacogenetic & pharmacokinetic biomarker for efavirenz based ARV and rifampicin based anti-TB drug induced liver injury in TB-HIV infected patients. PLoS One，2011，6(12):e27810. ［21］Cai Y, Yi J, Zhou C, et al. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. PLoS One，2012，7(10): e47769.［22］Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol，2008，23(2):192-202.［23］Hoffmann CJ, Charalambous S, Thio CL,et al.Hepatotoxicity in an African antiretroviral therapy cohort: the effect of tuberculosis and hepatitis B. AIDS，2007，21(10):1301-1308.［24］Torti C, Lapadula G, Casari S, et al. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infect Dis，2005，5:58.［25］Lima Mde F, Melo HR. Hepatotoxicity induced by antituberculosis drugs among patients coinfected with HIV and tuberculosis. Cad Saude Publica，2012，28(4):698-708.［26］Grupo Colaborativo En Hepatitis B. Clinical practice guideline for diagnosis and treatment of chronic hepatitis virus hepatitis B. Grupo Colaborativo en Hepatitis B［Article in Spanish］. Rev Gastroenterol Peru，2011，31(2):151-168. ［27］中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版). 中华传染病杂志,2011,29(2):65-80.［28］EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. EASL clinical practice guidelines: Management of hepatitis C virus infection.J Hepatol，2011，55(2):245-264.［29］中华医学会肝病学分会，中华医学会传染病与寄生虫病学分会.丙型肝炎防治指南.中华医学杂志,2004,84（9）：775-780.［30］游宏声,金生. 2011年欧洲肝病研究学会丙型肝炎防治指南推荐意见介绍.实用肝脏病杂志, 2011,14(4):307-308,320.［31］European Association for the Study of Liver. EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol，2012，57(2):399-420. ［32］Barve A, Khan R, Marsano L, et al.Treatment of alcoholic liver disease.Ann Hepatol，2008,7(1): 5-15.［33］中华医学会肝病学分会脂肪肝和酒精性肝病学组.酒精性肝病诊疗指南(2010年1月修订).胃肠病学,2010, 15 (10):617-621.［34］Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.Am J Gastroenterol，2012，107(6):811-826.［35］Loria P, Adinolfi LE, Bellentani S, et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee.Dig Liver Dis，2010，42(4):272-282.［36］中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪肝病诊疗指南(2010年修订版).胃肠病学和肝病学杂志,2010,19(6):483-487.［37］Gleeson D, Heneghan MA, British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut，2011，60(12): 1611-1629. ［38］张玉波,段维佳,贾继东. 2010 年美国肝病学会自身免疫性肝炎诊治指南要点.肝脏,2010, 15(5):367-371.［39］雷建平. 重新审视结核病免疫治疗研究的方向和方法. 中华临床医师杂志(电子版),2010,4(7)：908-915.［40］宿砚明,张宗明. 肝内胆汁淤积症的诊断和治疗.世界华人消化杂志，2008,16(11):1210-1214.［41］Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced liver disorders: report of an international consensus meeting. Int J Clin Pharmacol Ther Toxicol，1990，28(8):317-322. ［42］中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南（2012年版）.中华肝脏病杂志, 2012,21 (3):177-183.［43］Lv G, Zhao L, Zhang A, et al. Bioartificial liver system based on choanoid fluidized bed bioreactor improve the survival time of fulminant hepatic failure pigs. Biotechnol Bioeng，2011，108(9):2229-2236. ［44］Lee JH, Lee DH, Park JK, et al. Effect of fulminant hepatic failure porcine plasma supplemented with essential components on encapsulated rat hepatocyte spheroids. Transplant Proc，2012，44(4): 1009-1011. |
京公网安备11010202007215号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.
